CME
Podcast
Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
This PER® Spectives™ podcast episode features an interactive discussion on the evolving strategies in SCLC care. Key topics include the application of innovative therapeutic approaches, such as ADCs, bispecific antibodies, and novel treatments targeting DLL-3. This dynamic format explores ongoing challenges in SCLC management and discusses future clinical directions aimed at improving patient outcomes in real-world settings.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Amgen.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Instructions on How to Receive Credit
Today’s faculty are:
Anne Chiang, MD, PhD
Associate Professor Section of Medical Oncology
Yale School of Medicine
Associate Cancer Center Director, Clinical Initiatives
Yale Cancer Center
New Haven, CT
Disclosures: Grant/Research Support: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb; Advisory Board: Amgen, AstraZeneca, Daiichi Sankyo, Genentech, Janssen.
Erminia Massarelli, MD, PhD, MS
Division Chief, Hematology/Oncology
University of Texas at Tyler School of Medicine
Tyler, TX
Disclosures: Consultant/Advisory Board: AbbVie, AstraZeneca, Bristol Myers Squibb, Genentech, Johnson & Johnson, Sanofi.
Zofia Piotrowska, MD, MHS
Assistant Professor of Medicine, Harvard Medical School
Massachusetts General Hospital
Boston, MA
Disclosures: Grant/Research Support: AbbVie, AstraZeneca, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Janssen, Novartis, Spectrum Pharma, Takeda, Tesaro/GSK; Consultant: AstraZeneca, Bayer, Black Diamond Therapeutics, Boehringer Ingelheim, Eli Lilly, Genentech, Janssen, Merck, Sanofi, Taiho Pharma, Takeda; Other: Travel support: Janssen.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Release Date
January 28, 2025
Expiration Date
January 28, 2026